Despite this, one dose of anti-CLL-1 CAR-T resulted in CR for ten months in this patient, suggesting that CLL-1-specific CAR-T cells might be a useful tool in AML therapy [88]. This evidence concerns the gene CLEC12A and acute myeloid leukemia.